

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Rameen Beroukhim		Clinical Fellow in Oncology	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of California, Berkeley, CA	A.B.	1991	Physics and Philosophy
University of Cambridge, Cambridge, England	M.Phil.	1992	Molecular Biology
University of Cambridge, Cambridge, England	Ph.D.	1996	Molecular Biology
University of California, San Francisco, CA	M.D.	2000	Medicine

NOTE: The Biographical Sketch may not exceed four pages. Items A and B may not exceed two of the four-page limit.

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

Internship, Residency and Fellowship:

2000-2001	Intern in Medicine, University of California, San Francisco, CA
2001-2002	Junior Assistant Resident, Internal Medicine, University of California, San Francisco, CA
2000-2002	Fellow in Molecular Medicine, University of California, San Francisco, CA
2002-present	Clinical Fellow in Oncology, Harvard Medical School, Boston, MA
2002-present	Clinical Fellow in Oncology, Dana-Farber Cancer Institute, Boston, MA

Awards and Honors:

1990	Phi Beta Kappa
1991	High Honors in Physics, University of California, Berkeley, CA
1991	Winston Churchill Scholarship
1992	Glaxo Dorothy Hodgkin Scholarship
1992	Overseas Research Studentship (British Government award)
1996	Max Perutz Prize
2003	First Place, Poster Session, 1 st Annual Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE Retreat

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation.

1. Boess FG, **Beroukhim R**, Martin IL. Ultrastructure of the 5-Hydroxytryptamine₃ receptor. *J Neurochem* 1995. 64: 1401-1405.
2. **Beroukhim R**, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. *Neuron* 1995;15:323-331.
3. **Beroukhim R**, Unwin N. Distortion correction of tubular crystals: improvements in the acetylcholine receptor structure. *Ultramicroscopy* 1997; 70: 57-81
4. **Beroukhim R**. High-resolution electron crystallographic studies of ion channels. Ph.D. thesis, U. Cambridge 1997.
5. Paez JG, Lin M, **Beroukhim R**, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, Li C, Meyerson M, Sellers WR. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. *Nucleic Acids Research* 2004; 32:e71.
6. Rubin MA, Varambally S, **Beroukhim R**, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. *Cancer Research* 2004; 64:3814-3822.

7. Allinen M, **Beroukhim R**, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell* 2004; 64:17-32.
8. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, **Beroukhim R**, Milner DA, Granter SF, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative Genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005; 436:117-122.
9. Zhao X, Weir BA, LaFramboise T, Lin M, **Beroukhim R**, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Janne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. *Cancer Research* 2005; 65:5561-5570.

C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and responsibilities of principal investigator identified above.

PC040638 (Beroukhim)

11/01/2004-10/31/2006

Department of Defense

High-Resolution Mapping of Structural Mutations in Prostate Cancer with Single Nucleotide Polymorphism Arrays

1. To isolate DNA from 50 localized and 50 metastatic prostate cancers after laser-capture microdissection, along with DNA from corresponding germline tissue.
2. To generate genome-wide high-resolution maps of LOH and copy number alterations using SNP arrays containing probes for 120,000 markers.
3. To identify and validate candidate somatic genetic alterations differing in prevalence between localized and metastatic cancers, and develop markers for clinical association studies.

